Annual report pursuant to Section 13 and 15(d)

11. Stockholders' Equity (Details Narrative)

v3.3.1.900
11. Stockholders' Equity (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Prepayment on acquisition $ 3,744,517 $ 0
Research and development expense $ 3,434,016 $ 6,323,896
SynBio 2014 Warrant [Member]    
Warrant issued to purchase common stock   6,745,000
Warrant exercise price per share   $ 0.77
Warrants exercised 0 0
SynBio Partner Warrants [Member] | SynBio 2014 Warrant [Member]    
Warrant issued to purchase common stock   320,000
Warrants exercised 0 0
Serum Institute 2014 Warrant [Member]    
Warrant issued to purchase common stock   3,200,000
Fair value of warrant at date of grant   $ 480,000
Warrant exercise price per share   $ .77
Serum Institute 2014 Warrant [Member] | Serum Institute Partner Warrants [Member]    
Warrant issued to purchase common stock   160,000
Fair value of warrant at date of grant   $ 24,000
Warrants exercised 0 0
Warrant expense $ 706,500 $ 0
Asset Purchase Agreement [Member]    
Prepayment on acquisition $ 3,744,517  
Issuance of common stock in connection with pending asset acquisition, shares 11,000,000  
Non-Employee Director [Member]    
Warrant issued to purchase common stock   1,600,000
Fair value of warrant at date of grant   $ 240,000
Warrant exercise price per share   $ 0.77
Consultant [Member]    
Warrant issued to purchase common stock 833,000  
Fair value of warrant at date of grant $ 227,000  
Warrant exercise price per share $ .77  
Warrant expense $ 227,000  
Baxalta [Member]    
Stock issued for equity investment, shares 10,695,187  
custom:StockIssuedForEquityInvestment $ 10,000,000  
Non-Employee Director [Member]    
Warrant expense   $ 240,000